Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study
CONCLUSION: Our retrospective study confirms therapy resistance and dismal outcomes among patients with vCTCL.PMID:37271662 | DOI:10.1016/j.clml.2023.05.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 4, 2023 Category: Cancer & Oncology Authors: Tony Zibo Zhuang Ashley McCook-Veal Jeffrey Switchenko Tim Niyogusaba Erica S Tarabadkar Katelin Baird Colin O'Leary Darina Paulino Mary Jo Lechowicz Pamela B Allen Source Type: research
Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study
CONCLUSION: Our retrospective study confirms therapy resistance and dismal outcomes among patients with vCTCL.PMID:37271662 | DOI:10.1016/j.clml.2023.05.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 4, 2023 Category: Cancer & Oncology Authors: Tony Zibo Zhuang Ashley McCook-Veal Jeffrey Switchenko Tim Niyogusaba Erica S Tarabadkar Katelin Baird Colin O'Leary Darina Paulino Mary Jo Lechowicz Pamela B Allen Source Type: research
Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study
CONCLUSION: Our retrospective study confirms therapy resistance and dismal outcomes among patients with vCTCL.PMID:37271662 | DOI:10.1016/j.clml.2023.05.001 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 4, 2023 Category: Cancer & Oncology Authors: Tony Zibo Zhuang Ashley McCook-Veal Jeffrey Switchenko Tim Niyogusaba Erica S Tarabadkar Katelin Baird Colin O'Leary Darina Paulino Mary Jo Lechowicz Pamela B Allen Source Type: research
SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma
Clin Lymphoma Myeloma Leuk. 2023 May 11:S2152-2650(23)00143-X. doi: 10.1016/j.clml.2023.05.003. Online ahead of print.ABSTRACTIn this article, we will review current strategies for the front-line management of mantle cell lymphoma, an uncommon and biologically and clinically heterogeneous subtype of non-Hodgkin lymphoma that remains incurable with current therapies. Patients invariably relapse with time, and as a result, treatment strategies involve persistent therapy over the course of months to years, including induction, consolidation, and maintenance. Topics discussed include the historical development of various chemo...
Source: Clinical Lymphoma and Myeloma - June 2, 2023 Category: Cancer & Oncology Authors: Dilan Patel Brad Kahl Source Type: research
SOHO State of the Art Updates and Next Questions: Tailoring Upfront Therapy in Mantle Cell Lymphoma
Clin Lymphoma Myeloma Leuk. 2023 May 11:S2152-2650(23)00143-X. doi: 10.1016/j.clml.2023.05.003. Online ahead of print.ABSTRACTIn this article, we will review current strategies for the front-line management of mantle cell lymphoma, an uncommon and biologically and clinically heterogeneous subtype of non-Hodgkin lymphoma that remains incurable with current therapies. Patients invariably relapse with time, and as a result, treatment strategies involve persistent therapy over the course of months to years, including induction, consolidation, and maintenance. Topics discussed include the historical development of various chemo...
Source: Clinical Lymphoma and Myeloma - June 2, 2023 Category: Cancer & Oncology Authors: Dilan Patel Brad Kahl Source Type: research
CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease
Clin Lymphoma Myeloma Leuk. 2023 May 12:S2152-2650(23)00157-X. doi: 10.1016/j.clml.2023.05.007. Online ahead of print.NO ABSTRACTPMID:37263876 | DOI:10.1016/j.clml.2023.05.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 1, 2023 Category: Cancer & Oncology Authors: Uroosa Ibrahim Claude Bassil Julio C Chavez Farhad Khimani Michael D Jain Frederick L Locke Aleksandr Lazaryan Keren Osman Source Type: research
CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease
Clin Lymphoma Myeloma Leuk. 2023 May 12:S2152-2650(23)00157-X. doi: 10.1016/j.clml.2023.05.007. Online ahead of print.NO ABSTRACTPMID:37263876 | DOI:10.1016/j.clml.2023.05.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - June 1, 2023 Category: Cancer & Oncology Authors: Uroosa Ibrahim Claude Bassil Julio C Chavez Farhad Khimani Michael D Jain Frederick L Locke Aleksandr Lazaryan Keren Osman Source Type: research
Heart Failure Among Patients with Multiple Myeloma Treated with Carfilzomib-Based Versus Non-Carfilzomib-Based Regimens in the United States by Race
CONCLUSION: Although the IR of heart failure among patients with MM treated with a carfilzomib-based regimen was slightly higher, no evidence suggested the relative risk was different between White and Black patients with MM.PMID:37258396 | DOI:10.1016/j.clml.2023.04.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 31, 2023 Category: Cancer & Oncology Authors: Shuling Li Brandon T Suehs Alan Fu Laura Sangar é Chris Kim Victor M Gastanaga Jiannong Liu Heng Yan Yihua Xu Joseph Mikhael Source Type: research
A History and Current Understanding of Acute Erythroid Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Apr 28:S2152-2650(23)00139-8. doi: 10.1016/j.clml.2023.04.011. Online ahead of print.ABSTRACTAcute erythroid leukemia (AEL) is a highly aggressive subtype of acute myeloid leukemia. Since the first recognition of an erythroid-predominant hematologic malignancy in the early 20th century, AEL has gone through a turnstile of changing definitions and nomenclature, including eritoleucemia, erythremic myelosis, AML-M6 and pure erythroid leukemia. Ever-changing diagnostic criteria and under recognition have stifled our understanding of, and therapeutic options for, this rare erythroid-predominant ...
Source: Clinical Lymphoma and Myeloma - May 28, 2023 Category: Cancer & Oncology Authors: Coltoff Alexander Source Type: research
A History and Current Understanding of Acute Erythroid Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Apr 28:S2152-2650(23)00139-8. doi: 10.1016/j.clml.2023.04.011. Online ahead of print.ABSTRACTAcute erythroid leukemia (AEL) is a highly aggressive subtype of acute myeloid leukemia. Since the first recognition of an erythroid-predominant hematologic malignancy in the early 20th century, AEL has gone through a turnstile of changing definitions and nomenclature, including eritoleucemia, erythremic myelosis, AML-M6 and pure erythroid leukemia. Ever-changing diagnostic criteria and under recognition have stifled our understanding of, and therapeutic options for, this rare erythroid-predominant ...
Source: Clinical Lymphoma and Myeloma - May 28, 2023 Category: Cancer & Oncology Authors: Coltoff Alexander Source Type: research
A History and Current Understanding of Acute Erythroid Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Apr 28:S2152-2650(23)00139-8. doi: 10.1016/j.clml.2023.04.011. Online ahead of print.ABSTRACTAcute erythroid leukemia (AEL) is a highly aggressive subtype of acute myeloid leukemia. Since the first recognition of an erythroid-predominant hematologic malignancy in the early 20th century, AEL has gone through a turnstile of changing definitions and nomenclature, including eritoleucemia, erythremic myelosis, AML-M6 and pure erythroid leukemia. Ever-changing diagnostic criteria and under recognition have stifled our understanding of, and therapeutic options for, this rare erythroid-predominant ...
Source: Clinical Lymphoma and Myeloma - May 28, 2023 Category: Cancer & Oncology Authors: Coltoff Alexander Source Type: research
A History and Current Understanding of Acute Erythroid Leukemia
Clin Lymphoma Myeloma Leuk. 2023 Apr 28:S2152-2650(23)00139-8. doi: 10.1016/j.clml.2023.04.011. Online ahead of print.ABSTRACTAcute erythroid leukemia (AEL) is a highly aggressive subtype of acute myeloid leukemia. Since the first recognition of an erythroid-predominant hematologic malignancy in the early 20th century, AEL has gone through a turnstile of changing definitions and nomenclature, including eritoleucemia, erythremic myelosis, AML-M6 and pure erythroid leukemia. Ever-changing diagnostic criteria and under recognition have stifled our understanding of, and therapeutic options for, this rare erythroid-predominant ...
Source: Clinical Lymphoma and Myeloma - May 28, 2023 Category: Cancer & Oncology Authors: Coltoff Alexander Source Type: research
Comparison of Inpatient Outcomes Between HIV Positive and Negative Hospitalizations for Autologous Stem Cell Transplant Treatment among Lymphoid Malignancies
In this study we looked for differences in adverse hospital outcomes between those with and without HIV among hospitalizations for autologous stem cell transplantations (ASCTs) for lymphoid malignancies.MATERIALS AND METHODS: The current study was a retrospective analysis using the National Inpatient Sample (NIS) database, for the years 2005 to 2014. Adult hospitalizations ≥18 years of age, for ASCTs were included for the analysis, and were stratified into those with and without HIV. The primary outcome variables were in-hospital mortality, prolonged length of stay, and adverse dispositions.RESULTS: We included a total o...
Source: Clinical Lymphoma and Myeloma - May 27, 2023 Category: Cancer & Oncology Authors: Marco Ruiz Muni Rubens Venkataraghavan Ramamoorthy Carlo Briones Chavez Anshul Saxena Source Type: research
Monoclonal gammopathies of renal significance
Clin Med (Lond). 2023 May;23(3):250-253. doi: 10.7861/clinmed.2023-RM3.ABSTRACTThe term monoclonal gammopathies of renal significance (MGRS) encompasses a group of renal histopathological lesions fulfilling two criteria: (a) they are caused by nephrotoxic monoclonal immunoglobulins and (b) the monoclonal immunoglobulins are produced by small B-cell or plasma cell clones which do not meet the criteria for multiple myeloma or malignant lymphoma. Here, we provide a review of the MGRS definition and related terminology and elaborate on the diagnostic approach and treatment principles from the general physician perspective.PMID...
Source: Clinical Lymphoma and Myeloma - May 26, 2023 Category: Cancer & Oncology Authors: Sahana Gnanasampanthan Andreas Kousios Source Type: research
Clinical Outcomes in Patients With COVID-19 and Hematologic Disease
CONCLUSION: Patients with hematologic disease and COVID-19 have high mortality rates, predominantly due to COVID-19 complications. At a longer-term follow-up, no significant impact of COVID-19 on the course of a hematologic disease was revealed.PMID:37236904 | PMC:PMC10102503 | DOI:10.1016/j.clml.2023.04.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - May 26, 2023 Category: Cancer & Oncology Authors: Olga A Aleshina Kristina Zakurdaeva Anastasia N Vasileva Sergey K Dubov Vitaly S Dubov Vladimir I Vorobyev Lev S Butaev Alena M Sukhareva Lubov V Gavrilova Inessa Yu Toropova Marina O Popova Aleksandr A Siniaev Aleksandr D Kulagin Kamil D Kaplanov Andrei Source Type: research
